Literature DB >> 12038792

Differential regulation of human platelet responses by cGMP inhibited and stimulated cAMP phosphodiesterases.

J M Manns1, K J Brenna, R W Colman, S B Sheth.   

Abstract

Platelets contain two cAMP phosphodiesterases (PDEs) which regulate intracellular cAMP levels, cGMP-inhibited cAMP PDE (PDE3A) and cGMP-stimulated PDE (PDE2A). Using the PDE3 inhibitor, milrinone and the PDE2 inhibitor, erythro-9-(2-hydroxyl-3-nonyl)adenine (EHNA), we have explored the contribution of each PDE to the regulation of platelet function. Inhibition of PDE2 resulted in higher levels of intracellular cAMP than inhibition of PDE3A suggesting this PDE may be the more important regulator of cAMP in human platelets. However, a concentration-dependent inhibition of agonist-induced aggregation was observed with milrinone while little effect was seen with EHNA. In addition, we observed a concentration-dependent inhibition in the increase of intracellular Ca2+ with PDE3 inhibition and significantly less with PDE2 inhibition. PDE3 inhibition also resulted in a concentration-dependent increase in cAMP-mediated phosphorylation of the vasodilator-stimulated phospho-protein (VASP) whereas there was no significant increase with PDE2 inhibition. In each of these experiments, synergism was noted with the combination of milrinone and EHNA. These results suggest that cAMP pools may be localized and the various PDEs regulate specific pools. These data also suggest that inhibitors of PDE3A may be more effective antiplatelet agents.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12038792

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  6 in total

1.  Phosphodiesterase 3A binds to 14-3-3 proteins in response to PMA-induced phosphorylation of Ser428.

Authors:  Mercedes Pozuelo Rubio; David G Campbell; Nicholas A Morrice; Carol Mackintosh
Journal:  Biochem J       Date:  2005-11-15       Impact factor: 3.857

Review 2.  Cyclic nucleotide phosphodiesterases as targets for treatment of haematological malignancies.

Authors:  Adam Lerner; Paul M Epstein
Journal:  Biochem J       Date:  2006-01-01       Impact factor: 3.857

Review 3.  Anti-platelet therapy: phosphodiesterase inhibitors.

Authors:  Paolo Gresele; Stefania Momi; Emanuela Falcinelli
Journal:  Br J Clin Pharmacol       Date:  2011-10       Impact factor: 4.335

4.  Protein kinase C-mediated phosphorylation and activation of PDE3A regulate cAMP levels in human platelets.

Authors:  Roger W Hunter; Carol Mackintosh; Ingeborg Hers
Journal:  J Biol Chem       Date:  2009-03-04       Impact factor: 5.157

5.  Thrombin regulates intracellular cyclic AMP concentration in human platelets through phosphorylation/activation of phosphodiesterase 3A.

Authors:  Wei Zhang; Robert W Colman
Journal:  Blood       Date:  2007-03-28       Impact factor: 22.113

6.  Iloprost- and isoproterenol-induced increases in cAMP are regulated by different phosphodiesterases in erythrocytes of both rabbits and humans.

Authors:  Shaquria P Adderley; Eileen A Dufaux; Meera Sridharan; Elizabeth A Bowles; Madelyn S Hanson; Alan H Stephenson; Mary L Ellsworth; Randy S Sprague
Journal:  Am J Physiol Heart Circ Physiol       Date:  2009-02-27       Impact factor: 4.733

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.